Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales
Authors
Keywords
-
Journal
Future Microbiology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2020-04-17
DOI
10.2217/fmb-2020-0012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia
- (2019) Shampa Das et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients
- (2019) Vasiliki Tsolaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
- (2019) Sarah C J Jorgensen et al. Open Forum Infectious Diseases
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations
- (2018) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae
- (2018) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development
- (2018) Sherwin K. B. Sy et al. CLINICAL PHARMACOKINETICS
- Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups
- (2018) Jianguo Li et al. CTS-Clinical and Translational Science
- CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM
- (2018) C. De la Calle et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
- (2018) Alessandro Cassini et al. LANCET INFECTIOUS DISEASES
- KPC-PRODUCING KLEBSIELLA PNEUMONIAE GUT DECOLONIZATION AFTER CEFTAZIDIME/AVIBACTAM-BASED COMBINATION THERAPY: A RETROSPECTIVE OBSERVATIONAL STUDY
- (2018) Matteo Bassetti et al. Journal of Global Antimicrobial Resistance
- Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation
- (2017) Fiorella Krapp et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
- (2017) Xinyu Qin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
- (2017) Juan J. Castón et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
- (2017) Latania K. Logan et al. JOURNAL OF INFECTIOUS DISEASES
- Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program
- (2016) Elizabeth Temkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Combination treatment with extended-infusion ceftazidime/avibactam for a KPC-3-producing Klebsiella pneumoniae bacteraemia in a kidney and pancreas transplant patient
- (2016) David M. Jacobs et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae
- (2016) Isabel Machuca et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment
- (2016) Henri Merdjan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
- (2016) Yehuda Carmeli et al. LANCET INFECTIOUS DISEASES
- Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae
- (2016) Elizabeth A. Neuner et al. Virulence
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
- (2015) Henri Merdjan et al. CLINICAL DRUG INVESTIGATION
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Multidrug-resistant Gram-negative bacteria: a product of globalization
- (2015) P.M. Hawkey JOURNAL OF HOSPITAL INFECTION
- The β-Lactams Strike Back: Ceftazidime-Avibactam
- (2015) Evan J. Zasowski et al. PHARMACOTHERAPY
- Oral Gentamicin Gut Decontamination for Prevention of KPC-Producing Klebsiella pneumoniae Infections: Relevance of Concomitant Systemic Antibiotic Therapy
- (2014) Carlo Tascini et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
- (2014) J. A. Roberts et al. CLINICAL INFECTIOUS DISEASES
- Prolonging β-lactam infusion: A review of the rationale and evidence, and guidance for implementation
- (2013) Shawn H. MacVane et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe
- (2012) R. Cantón et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia
- (2012) A. E. Muller et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections
- (2008) Peggy S. McKinnon et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
- (2008) Johann DD Pitout et al. LANCET INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search